In the ever-evolving field of psychiatry, staying up to date with the latest news and research can prove difficult. To save you some time, here’s your curated dose of this month’s psychiatry news.
This month, the FDA approved new ADHD medication in adolescence, and a new U.S. law goes into effect requiring patients access to clinician’s notes. Additionally, new studies indicate how type 2 diabetes and stroke survivors are at an increased risk for developing psychiatric conditions.
Read on for these and more top stories:
FDA Clears Nonstimulant for ADHD in Kids 6 Years and Up Medscape, April 05, 2021
The US Food and Drug Administration (FDA) has approved the nonstimulant medication viloxazine extended-release capsules (Qelbree, Supernus Pharmaceuticals) for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 to 17 years.
Starting April 5, patients can read your notes: 5 things to consider Medscape, April 1, 2021
April 5 is the official start date of a U.S. law requiring health care organizations to provide patients with free, full, and immediate electronic access to their doctor’s clinical notes as well as test results and reports from pathology and imaging.
Infographic: A Snapshot of Psychiatrists’ Attitudes Toward Cannabis Psychiatric Times, March 17, 2021
Research on psychiatrists’ attitudes on the potential of cannabis in psychiatry.
Type 2 diabetes linked to increased risk for Parkinson’s Everyday Health, March 17, 2021
People managing type 2 diabetes and their doctors may need to have Parkinson’s disease on their radar, as new research sheds light on the possible connection between these two chronic health conditions.
Suicide risk elevated among stroke survivors Healio, March 17, 2021
Stroke survivors may be more likely to attempt or die by suicide than people who have not had a stroke, according to a meta-analysis presented at the American Stroke Association’s virtual International Stroke Conference.